Stockreport

Royalty Pharma: 2025 Financial Performance And Strategic Outlook [Seeking Alpha]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF RPRX expanded its portfolio through $2.6B in new royalty transactions, $1.2B in share repurchases, and a 7% dividend increase entering 2026. Synthetic royalties emerg [Read more]